Neuron Bio patents two new molecules that enter more efficiently into the brain and avoid neuronal death

The Spanish Patent and Trademark Office (SPTO) has granted Neuron Bio with a patent for two compounds that protect neuronal death and penetrate with high efficiency into the brain, two essential features to be used as treatments that delay the start of Alzheimer’s disease and other neurodegenerative disorders.

The patent protects the use of the compounds, which are internally named NST0076 and NST0078 and have been selected for their anti-inflammatory neuroprotective and antiepileptic capacities. The compounds are potentially effective as treatment for neurodegenerative diseases or disorders of the nervous system, concretely for its application in the Alzheimer’s disease and epilepsy.

Javier Burgos, CEO of the company has made a very positive appraisal of this news and stated, “These compounds have been developed thanks to the expertise accumulated by the researchers of the company after evaluating thousands of potential candidates, using company’s own exclusive drug discovery platform that includes models of this disease in human cells and animal models.”